Statins and Glaucoma: Can Cholesterol Drugs Protect

What did the study find about statins and glaucoma?

Researchers used the TriNetX health-records database to compare adults over 40 with recorded statin use against matched nonusers. Published in the British Journal of Ophthalmology, the retrospective study reported a hazard ratio of 0.85 for developing open-angle glaucoma over five years, indicating a 15% lower relative hazard among statin users. This measures an association over time; it does not demonstrate that the medicines prevented disease. [Original study](https://pubmed.ncbi.nlm.nih.gov/42838727/)

The University of California San Diego reported five-year diagnosis proportions of 2.3% among statin users and 2.6% among controls. Calculated from those rounded figures, the difference is approximately three fewer diagnoses per 1,000 people. That absolute comparison helps put the relative finding into perspective, but it cannot be interpreted as an established treatment benefit. [UC San Diego research report](https://today.ucsd.edu/story/statins-may-protect-people-from-developing-glaucoma)

A separate analysis of people with glaucoma linked statin use to fewer incisional operations, minimally invasive glaucoma procedures and laser treatments. Associations persisted at ten years. These outcomes describe treatment decisions recorded in healthcare data; they do not directly establish that patients retained better vision. [Study results](https://pubmed.ncbi.nlm.nih.gov/42838727/)

Could statins protect the optic nerve independently of cholesterol?

Statins are being investigated for biological effects beyond cholesterol reduction, including effects on inflammation and nerve-cell survival. Those possibilities make them interesting candidates for glaucoma research. However, the investigators lacked individual eye-pressure measurements and detailed surgical information. They could not determine whether procedures reflected worsening disease or problems following treatment, limiting conclusions about how statins might affect the eye. [Research findings and limitations](https://today.ucsd.edu/story/statins-may-protect-people-from-developing-glaucoma)

The wider evidence is also inconsistent. A separate population-based study published in Investigative Ophthalmology & Visual Science found associations between statin use and higher rates of ocular hypertension and primary open-angle glaucoma in people with high cholesterol. Differences in populations, medication exposure and study methods may help explain the conflicting results. That study also cannot establish causation. [Population-based study](https://pmc.ncbi.nlm.nih.gov/articles/PMC12697695/)

A central methodological concern is that matching patients cannot remove every difference between people prescribed a medicine and those who are not. Healthcare attendance, underlying illness and medication-taking behavior could influence recorded outcomes. A randomized trial would provide a stronger test of whether adding a statin changes glaucoma progression, particularly if it measured visual-field deterioration and optic-nerve damage alongside treatment use.

Should people take statins to prevent or treat glaucoma?

According to the National Eye Institute, glaucoma damages the optic nerve and can develop without noticeable early symptoms. Established treatments include pressure-lowering eye drops, laser procedures and surgery. These treatments can help prevent further damage but cannot reverse vision already lost. Regular eye examinations and follow-up therefore remain essential, including for people whose cholesterol is well controlled. [National Eye Institute guidance](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/glaucoma)

Statin prescribing should continue to reflect established cardiovascular indications and an individual's overall health. The NHS explains that these medicines reduce cholesterol production and help prevent heart attacks and strokes in appropriate patients. They can also cause side effects, including muscle pain, and interact with other medicines. An uncertain eye benefit is insufficient reason to start treatment, increase a dose or switch products independently. [NHS statin guidance](https://www.nhs.uk/medicines/statins/)

For patients already taking a statin, the practical step is to keep both their prescribing clinician and eye specialist informed about their medicines. Any future glaucoma indication would need evidence identifying who benefits, which regimen works and whether the benefit outweighs additional treatment burdens.